Palantir's Valuation Reflects Priced-In Success; Wait for Confirmation

What happened

Palantir's recent stock performance already reflects a 'ton of success,' as a new article notes, highlighting the risk that expectations are too high. The DeepValue Master Report reinforces this caution, assigning a WAIT rating with a conviction of 4.0, citing a P/E of 137.1 and EV/EBITDA of 177 that leave no room for error. While Q1'26 results were superb ($1.633B revenue, +85% YoY, and strong cash flow), the report stresses that the underlying contracts are option-heavy and terminable for convenience, meaning headline deal values may not fully convert to revenue. The key near-term test is whether Q1's $1.176B U.S. commercial TCV and $4.5B RPO sustain sequential growth and retention of the ~39% next-12-month RPO share. Until this conversion evidence emerges, the report suggests waiting for either confirmation or a lower entry near $110.

Implication

Palantir's valuation already prices in significant success, leaving little room for disappointment. The next earnings report must show U.S. commercial TCV and RDV maintaining sequential growth from Q1's elevated levels. If backlog quality holds and the RPO near-term share stays near 39%, the thesis could shift toward a buy. However, if conversion stalls or options are not exercised, downside to $95 or lower is likely given the multiple compression risk. The highest expected-value action is to wait for either confirmation or a re-entry near $110.

Thesis delta

The Motley Fool article aligns with the DeepValue report's assessment that Palantir's valuation reflects priced-in success. Neither source suggests a change in the WAIT stance; both emphasize the need for conversion confirmation. The thesis remains that until the next quarter proves sustained demand conversion, the risk/reward favors waiting.